Stifel analyst Bradley Canino reiterated a Buy rating and $155.00 price target on Blueprint Medicines (NASDAQ: BPMC).The analyst commented, "While ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE